CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, ...
Intellia Therapeutics, Inc, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced the first patient has been dosed in MAGNITUDE-2, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback